Ul­tragenyx wins pri­or­i­ty re­view for buro­sum­ab; Gen­fit rais­ing €150M for PhI­II NASH study

→ Ul­tragenyx $RARE and its part­ners at Ky­owa Hakko Kirin land­ed a pri­or­i­ty re­view for buro­sum­ab to treat pe­di­atric and adult pa­tients with X-Linked Hy­pophos­phatemia. The ac­cel­er­at­ed PR gives them a shot at an April 17, 2018 PDU­FA date.

→ Gen­fit (Eu­ronext: GN­FT) is rais­ing €150 mil­lion so it can wrap up its Phase III for elafi­bra­nor in NASH and take the da­ta to reg­u­la­tors.

→ France’s Bio­phytis has raised €10.4 mil­lion for mid-stage stud­ies of its drugs for age-re­lat­ed dis­eases. The biotech is work­ing on sar­cope­nia and age-re­lat­ed mac­u­lar de­gen­er­a­tion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.